Article
FDA approves Amgen drug for lung cancer with specific mutation
Rating:
0.0
Views:
185
Likes:
1
Library:
1
The FDA approved an Amgen drug for non-small cell lung cancer with the KRAS gene mutation in patients whose disease has worsened after other treatments.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value